Surface Oncology's strategy to improve on the first generation of immuno-oncology drugs. Their Phase 2 trials in lung cancer and liver cancer are underway and recruiting.

Prothena's 1-2-3 punch for Alzheimer’s + their work in Parkinson’s, ALS, and the role of Amyloids in Down Syndrome

In a long-form feature from Tech Nation, it’s Pulitzer Prize-winning author, Edward Humes, with “The Forever Witness … How DNA and Genealogy Solved a Cold Case Double Murder.” We get an object lesson in the Three Ages of DNA from a forensic investigation standpoint, and while it reads like a fast-paced Cold Case on steroids – it provides details no fiction writer would dare to make up, including the unexpected involvement of the famous true crimes writer, Ann Rule, and a person whose DNA skills are familiar to fans of the PBS documentary series, “Finding Your Roots with Henry Louis Gates, Jr.”

A new global company with 64 products, many of which are for women? Kevin Ali is the CEO of Organon.

Cancer is a hijacker, hijacking cells for its own purposes. And that’s where eFFECTOR Therapeutics is determined to intervene. Dr. Steve Worland, the Co-Founder & CEO, talks about just two of the candidates in its pipeline: One is for Non-small cell lung cancer and another for ER+ breast cancer, with these and other clinical trials enrolling now.

Like the idea of replacing some of your DNA with DNA that works better? And what if you want that new DNA to stop? Dr. Alexandria Forbes, the President & CEO of MeiraGTx, tells us about their work in retinitis pigmentosa and Parkinson’s – two of many clinical trials enrolling right now.

Vor Biopharma has a unique approach to a particular kind of cancer – Acute Myeloid Leukemia – perhaps better known to you, as AML. Dr. Robert Ang is Vor's President & CEO.

Too much of a good thing spells trouble - in this case, that would be neutrophils – the white blood cells that act as our immune system’s first line of defense. It's called PPP, or Palmoplantar Pustulosis. Dr. James Mackay is the President & CEO of Aristea Therapeutics.